Elevara Medicines

About Elevara Medicines

Elevara Medicines is a clinical-stage biotechnology company developing therapies for rheumatoid arthritis (RA) and other chronic inflammatory diseases. The company was founded in 2025 and is headquartered in London, UK. Elevara was co-founded by Weatherden, a UK-based clinical advisory group, and Monograph Capital, which provided initial funding and operational support. The leadership team includes CEO Emma Tinsley and Chief Medical Officer Professor Dominique Baeten, MD, PhD.

The company's business model is centered on developing and commercializing novel therapeutics. In October 2025, Elevara secured $70 million in a Series A financing round co-led by Forbion and Sofinnova Partners, with participation from founding investors Monograph Capital and Weatherden. This capital is intended to fund the advancement of its lead candidate, ELV001, through a Phase 2 clinical trial and to support exploratory programs in other inflammatory conditions and women's health. Elevara gained the exclusive global rights to develop, commercialize, and manufacture ELV001 from Japan's Teijin Pharma, which had dedicated over a decade of scientific work to the program.

Elevara's lead program, ELV001, is a first-in-class oral CDK4/6 inhibitor. Unlike traditional RA treatments that broadly suppress the immune system, ELV001 selectively targets fibroblast-like synoviocytes (FLS), which are key cells contributing to joint inflammation and damage in RA. This approach is designed to be an add-on therapy for RA patients who have an inadequate response to standard-of-care treatments like methotrexate and TNF inhibitors. By focusing on synovial fibroblasts rather than immune cells, ELV001 aims to work in conjunction with approved immunomodulators to achieve better outcomes for patients who fail to reach remission. The upcoming START-SYNERGY Phase 2 trial is set to enroll approximately 180 patients to evaluate the drug's efficacy.